IRadimed (IRMD) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

IRadimed (IRMD) overview

IRadimed (IRMD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 83.8m and operating profit of USD 26.1m; the year-end share price was 97.28 USD and market capitalisation was USD 1,243m. IRadimed is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get IRadimed's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 94.6mFY 2025
Share price97.28 USDFY 2025 year end
RevenueUSD 83.8mFY 2025
Operating profitUSD 26.1mFY 2025
Net earningsUSD 22.5mFY 2025
Market capitalisationUSD 1,243mFY 2025 year end

About IRadimed

IRadimed develops, manufactures, markets, and distributes medical devices and related products and services designed for use during magnetic resonance imaging procedures. Its portfolio includes MRI-compatible intravenous infusion pump systems, disposable tubing, mounting equipment, and remote displays, as well as a patient vital signs monitoring system. These products support clinicians caring for patients during MRI scans.

Generate the IRadimed report

IRadimed is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for IRadimed and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on IRadimed

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.